Quantcast

Genome sequencing platform Personalis files for a $115 million IPO


Shutterstock photo

Personalis, which provides a genome sequencing platform for cancer research, filed on Thursday with the SEC to raise up to $115 million in an initial public offering.

The Menlo Park, CA-based company was founded in 2011 and booked $48 million in sales for the 12 months ended March 31, 2019. It plans to list on the Nasdaq under the symbol PSNL. Personalis filed confidentially on March 27, 2019. Morgan Stanley, BofA Merrill Lynch and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Genome sequencing platform Personalis files for a $115 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe







Renaissance Capital
Contributor:

Renaissance Capital

IPOs












Research Brokers before you trade

Want to trade FX?